Pluvicto is indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy or who are not medically suitable for taxanes.
Advanced Accelerator Applications announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...
This guideline covers assessing and managing oesophago-gastric cancer in adults, including radical and palliative treatment and nutritional support.
This guideline covers rehabilitation strategies for adults who have experienced a critical illness and stayed in critical care.
This guideline is restricted to GI endoscopy but we cover elective and acute or emergency procedures.
Lutathera is indicated for the treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adults.
Advanced Accelerator Applications (AAA), a Novartis company, announced that the Medicines & Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation in Great Britain for lutetium (177Lu) vipivotide tetraxetan, for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy or who are not medically suitable for taxanes.